EMA Recommends Extension of Therapeutic Indications for Niraparib / Abiraterone Acetate By Ogkologos - February 20, 2026 286 0 Facebook Twitter Google+ Pinterest WhatsApp New combination concerns a combination with ADT for the treatment of adult patients with mHSPC and BRCA1/2 mutations Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Neoadjuvant Atezolizumab Plus Chemotherapy Is Safe and Has Promising Activity in... January 11, 2024 French Senate Committee Backs ESMO Call to Revise EU Regulation to... June 17, 2025 Osimertinib After Definitive Chemoradiotherapy Prolongs PFS in Patients with Unresectable Stage... June 6, 2024 Miss New Jersey Collegiate USA Uses Her Prestigious Position to Shed... March 31, 2021 Load more HOT NEWS Undetectable MRD and Extended PFS More Common with MRD-guided Ibrutinib-Venetoclax than... Minimizing Time Between Diagnosis and End of Treatment Improves Breast Cancer... Cancer Patients May Soon Be Able to Get an Entire Course... Quadruplet Isa-KRd Regimen Improves NGS-MRD Negativity in Transplant-Eligible Patients with Newly...
